EGFR and B-cell non-Hodgkin lymphoma: IL-15 has been shown to increase Cetuximab-mediated cellular toxicity against triple-negative breast cancer cell lines expressing EGFR (35) and Rituximab-mediated cellular toxicity against B cell lymphoma cell expressing CD20 (34).